Skip to main content

Table 3 Risk of reduced overall survival by plasma levels of C-reactive protein and prognostic factors

From: Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study

    

Tertiles of C-reactive protein (mg/L)

 

Stratification

No. of patients

No. of deaths

P, inter-action

1st (<1.04)

2nd (1.04 to 3.24)

3rd (>3.24)

P, trend

    

Multifactor-adjusted hazard ratio (95% CI)

 

None

2,910

383

 

1.0

1.29 (0.96 to 1.72)

1.84 (1.39 to 2.45)

<0.001

Age at diagnosis

       

   <57 years

964

74

0.40

1.0

0.97 (0.49 to 1.90)

1.69 (0.91 to 3.14)

0.08

   57 to 69 years

964

103

 

1.0

1.76 (0.99 to 3.11)

2.53 (1.42 to 4.50)

0.002

   ≥69 years

982

206

 

1.0

1.18 (0.78 to 1.79)

1.59 (1.07 to 2.37)

0.01

Tumour size

       

   ≤20 mm

1,501

119

0.33

1.0

1.02 (0.62 to 1.68)

1.66 (1.03 to 2.68)

0.03

   20 to 50 mm

1,409

264

 

1.0

1.48 (1.02 to 2.15)

2.04 (1.41 to 2.95)

<0.001

   >50 mm

103

23

 

1.0

2.74 (0.36 to 20.7)

0.63 (0.06 to 6.61)

0.44

Lymph node status

       

   Lymph node negative

1,334

132

0.59

1.0

1.07 (0.65 to 1.76)

1.48 (0.92 to 2.38)

0.08

   Lymph node positive

1,335

191

 

1.0

1.55 (1.01 to 2.38)

2.04 (1.33 to 3.12)

0.001

Distant metastases

       

   No

2,780

343

0.66

1.0

1.31 (0.96 to 1.78)

1.80 (1.33 to 2.44)

<0.001

   Yes

40

23

 

1.0

0.50 (0.01 to 21.0)

15.6 (1.10 to 221)

0.03

Tumour grade

       

   Well differentiated

685

50

0.69

1.0

0.74 (0.31 to 1.75)

1.49 (0.68 to 3.28)

0.21

   Moderately differentiated

1,262

154

 

1.0

1.17 (0.74 to 1.88)

1.78 (1.14 to 2.77)

0.007

   Poorly/un-differentiated

505

92

 

1.0

2.19 (1.16 to 4.14)

2.23 (1.14 to 4.39)

0.03

Estrogen receptor status

       

   Positive

2,233

234

0.83

1.0

1.07 (0.74 to 1.55)

1.59 (1.11 to 2.28)

0.005

   Negative

436

88

 

1.0

2.07 (1.08 to 3.98)

2.74 (1.44 to 5.19)

0.002

Progesterone receptor status

       

   Positive

1,383

87

0.60

1.0

1.83 (0.93 to 3.59)

2.37 (1.23 to 4.58)

0.01

   Negative

787

130

 

1.0

1.47 (0.88 to 2.47)

2.22 (1.33 to 3.71)

0.002

HER2 status

       

   Positive

807

29

0.11

1.0

1.64 (0.34 to 7.96)

8.63 (2.04 to 36.4)

<0.001

   Negative

220

19

 

1.0

1.24 (0.24 to 6.49)

1.29 (0.31 to 5.45)

0.74

  1. Blood samples were drawn and CRP measured at time of diagnosis of breast cancer.
  2. Hazard ratios are multifactor-adjusted for age at diagnosis, tumour size, lymph node status, presence of distant metastases, tumour grade, and estrogen receptor, progesterone receptor, and HER2 status, smoking, alcohol consumption, body mass index, menopause status, and cardiovascular disease (Model 3), excluding the factor stratified for; however, age stratified analyses were still adjusted for age.
  3. Due to differences in numbers of missing values for the covariates in question, numbers of patients and deaths do not necessarily add up to 2,910 and 383, respectively.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us